Summit Therapeutics Inc.
SMMT
$17.43
-$1.48-7.83%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 64.01% | 67.09% | 72.95% | 80.65% | -680.54% |
| Total Depreciation and Amortization | -55.05% | -87.30% | -92.45% | -93.21% | -92.12% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -88.18% | -89.12% | -91.89% | -96.68% | 1,965.54% |
| Change in Net Operating Assets | 3,099.81% | 703.15% | 211.57% | -67.47% | -105.99% |
| Cash from Operations | -85.13% | -116.64% | -113.01% | -162.55% | -84.60% |
| Capital Expenditure | -8.59% | -9.48% | -183.72% | 75.00% | 79.49% |
| Sale of Property, Plant, and Equipment | -- | -100.00% | -100.00% | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 65.09% | 64.82% | 80.93% | 111.94% | -- |
| Cash from Investing | 65.06% | 64.79% | 80.91% | 111.96% | -94,094.55% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -305.09% | -205.84% | 100.00% | 100.00% | 1.26% |
| Issuance of Common Stock | 328.87% | 362.07% | 0.98% | -96.42% | 11.76% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -1,306.82% | 100.00% | 88.47% | -299.35% |
| Cash from Financing | 340.66% | -31.52% | -69.31% | -98.98% | -86.05% |
| Foreign Exchange rate Adjustments | -102.15% | -81.36% | -72.73% | 158.66% | 168.66% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 105.85% | 171.61% | 12.20% | -44.39% | -200.06% |
